9.11
price up icon5.93%   0.51
after-market After Hours: 9.10 -0.010 -0.11%
loading
Monte Rosa Therapeutics Inc stock is traded at $9.11, with a volume of 627.58K. It is up +5.93% in the last 24 hours and up +86.30% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$8.60
Open:
$8.73
24h Volume:
627.58K
Relative Volume:
0.29
Market Cap:
$546.79M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-3.5447
EPS:
-2.57
Net Cash Flow:
$-67.76M
1W Performance:
+8.97%
1M Performance:
+86.30%
6M Performance:
+118.99%
1Y Performance:
+203.67%
1-Day Range:
Value
$8.61
$9.25
1-Week Range:
Value
$8.0363
$9.25
52-Week Range:
Value
$2.92
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Name
Monte Rosa Therapeutics Inc
Name
Phone
617-949-2643
Name
Address
321 HARRISON AVENUE, BOSTON
Name
Employee
103
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLUE
Monte Rosa Therapeutics Inc
9.11 546.79M 0 -130.41M -67.76M -2.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.56 119.70B 10.63B -479.80M -1.35B 13.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.87 82.75B 13.85B 4.65B 3.32B 35.06
Biotechnology icon
ARGX
Argen X Se Adr
614.59 36.73B 1.86B -40.29M -1.28B -4.16
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.74 32.53B 2.09B -332.26M 16.06M -4.14
Biotechnology icon
BNTX
Biontech Se Adr
120.72 28.50B 3.30B -501.07M 1.03B 11.54

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-15-24 Initiated Wedbush Outperform
Jan-03-23 Upgrade Wells Fargo Equal Weight → Overweight
Oct-13-22 Initiated UBS Buy
Aug-15-22 Initiated Jefferies Buy
Apr-28-22 Initiated Credit Suisse Neutral
Feb-10-22 Initiated Wells Fargo Equal Weight
Oct-14-21 Initiated SVB Leerink Mkt Perform
View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

pulisher
Nov 26, 2024

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - The Manila Times

Nov 26, 2024
pulisher
Nov 26, 2024

Monte Rosa Therapeutics CEO to Present at Piper Sandler Healthcare Conference | GLUE Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 26, 2024

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference - GlobeNewswire Inc.

Nov 26, 2024
pulisher
Nov 20, 2024

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - MSN

Nov 20, 2024
pulisher
Nov 16, 2024

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024
pulisher
Nov 13, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St

Nov 12, 2024
pulisher
Nov 11, 2024

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance

Nov 11, 2024
pulisher
Nov 11, 2024

Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 31, 2024

Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World

Oct 31, 2024
pulisher
Oct 31, 2024

Biogen, Neomorph pact worth $1.45B for molecular glue degraders - BioWorld Online

Oct 31, 2024
pulisher
Oct 30, 2024

Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Novartis adds another degrader, this time from Monte Rosa - BioCentury

Oct 28, 2024
pulisher
Oct 28, 2024

This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Boston Biotech Announces Novartis Collaboration - Streetwise Reports

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals

Oct 28, 2024
pulisher
Oct 28, 2024

Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive

Oct 28, 2024
pulisher
Oct 28, 2024

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com

Oct 28, 2024

Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price down icon 1.35%
$75.45
price up icon 0.87%
$43.39
price up icon 3.19%
$378.13
price up icon 0.30%
$206.16
price up icon 7.31%
$120.72
price up icon 1.84%
Cap:     |  Volume (24h):